I'm LongbridgeAI, I can summarize articles.CVS Health (CVS) rose 0.33% this week to close at $89.13, while the S&P 500 gained 1.21%, leaving the stock about 0.88 percentage points behind the benchmark. Trading was backloaded: the shares slipped from $87.60 on Monday to a low of $84.50 by Thursday, then rebounded 4.79% on Friday to finish near the high of the week. Average daily volume of 9.9m shares ran about 39.84% above the median, pointing to higher activity.
The Week
CVS Health (CVS) rose 0.33% this week to close at $89.13, while the S&P 500 gained 1.21%, leaving the stock about 0.88 percentage points behind the benchmark. Trading was backloaded: the shares slipped from $87.60 on Monday to a low of $84.50 by Thursday, then rebounded 4.79% on Friday to finish near the high of the week. Average daily volume of 9.9m shares ran about 39.84% above the median, pointing to higher activity.
Key Events
The week’s news centred on the company’s retail and health services operations. Early reports named CVS among health care stocks that could rally in September. As measles cases rose in Tennessee, CVS reminded residents that vaccines were available statewide. Retail-related items included CON-CRĒT® Creatine HCl expanding into Target and CVS, and the company launching a national “Wear Your HeART” bandage art contest. Late in the week, CVS said it was strengthening energy resilience to support patient care. Legal notes also surfaced around website user payments and insider fiduciary duties.
Analyst Ratings
Twenty-seven brokers cover CVS: 18 rate it buy, 7 rate it overweight, and 2 rate it hold, with no sell or underweight ratings. The consensus rating is strong buy, and the consensus target price of $116.28 sits about 30.46% above the latest price. Targets range from $103.00 to $148.00, a wide band that reflects disagreement on the upside. Within the health care services industry, CVS ranks second among 53 covered names.
The Week Ahead
Next week opens with a run of US macro data: the Dallas Fed manufacturing activity index on 28 September, followed on 29 September by FHFA home prices, Case-Shiller home price indices, JOLTS job openings, and consumer confidence. These releases will set the tone for rate and consumption expectations, which may feed into health care sentiment. The website user payment notice also leaves a potential follow-up item to watch.
In Short
The stock started weak and finished strong, with Friday’s bounce narrowing its gap against the market. The rating picture is constructive, with the consensus target above spot, while the 23.3x P/E sits in a middling range. The latest session’s capital flow showed large-lot money as a net seller and small-lot money as a net buyer, a split direction. The next checkpoints are next week’s macro figures and the pace of CVS’s retail and health service initiatives.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.